Chromosomal translocation products engender new intracellular therapeutic technologies
- 1 April 2003
- journal article
- review article
- Published by Springer Nature in Nature Medicine
- Vol. 9 (4) , 383-386
- https://doi.org/10.1038/nm0403-383
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformationThe EMBO Journal, 2003
- RNA interference: advances and questionsPhilosophical Transactions Of The Royal Society B-Biological Sciences, 2002
- Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemiaSeminars in Hematology, 2001
- Design and Selection of Novel Cys2His2 Zinc Finger ProteinsAnnual Review of Biochemistry, 2001
- Masked antisense: a molecular configuration for discriminating similar RNA targetsEMBO Reports, 2000
- CML vaccines as a paradigm of the specific immunotherapy of cancerBlood Reviews, 2000
- Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APLNature Genetics, 1998
- Regulation of gene expression by small moleculesNature, 1997
- Chromosomal translocations in human cancerNature, 1994
- Transgenic Models of Tumor DevelopmentScience, 1991